Qiagen (NYSE:QGEN) Shares Sold by SG Americas Securities LLC

SG Americas Securities LLC trimmed its position in Qiagen (NYSE:QGEN) by 6.6% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 464,202 shares of the company’s stock after selling 32,749 shares during the period. SG Americas Securities LLC owned approximately 0.20% of Qiagen worth $21,154,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Riverview Trust Co acquired a new stake in shares of Qiagen during the first quarter worth $28,000. Toronto Dominion Bank acquired a new position in Qiagen during the second quarter valued at $27,000. Park Place Capital Corp acquired a new position in Qiagen during the first quarter valued at $36,000. Massmutual Trust Co. FSB ADV lifted its position in Qiagen by 39.8% during the third quarter. Massmutual Trust Co. FSB ADV now owns 853 shares of the company’s stock valued at $39,000 after purchasing an additional 243 shares during the period. Finally, Quarry LP acquired a new position in Qiagen during the fourth quarter valued at $38,000. 70.00% of the stock is currently owned by institutional investors and hedge funds.

Qiagen Price Performance

QGEN traded up $0.03 on Friday, reaching $43.57. 871,753 shares of the company’s stock were exchanged, compared to its average volume of 1,200,263. The stock has a market cap of $9.94 billion, a PE ratio of 29.22, a P/E/G ratio of 3.23 and a beta of 0.39. Qiagen has a twelve month low of $34.74 and a twelve month high of $47.44. The stock’s fifty day moving average price is $45.40 and its 200-day moving average price is $43.50. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.77 and a quick ratio of 1.46.

Qiagen (NYSE:QGEN) last posted its quarterly earnings results on Wednesday, July 31st. The company reported $0.55 earnings per share for the quarter, topping analysts’ consensus estimates of $0.52 by $0.03. The firm had revenue of $496.00 million for the quarter, compared to analyst estimates of $495.45 million. Qiagen had a net margin of 3.75% and a return on equity of 12.92%. Qiagen’s quarterly revenue was down .2% on a year-over-year basis. During the same period in the previous year, the business posted $0.53 earnings per share. Sell-side analysts expect that Qiagen will post 2.15 EPS for the current year.

Analysts Set New Price Targets

QGEN has been the subject of a number of research reports. JPMorgan Chase & Co. boosted their target price on shares of Qiagen from $52.00 to $54.00 and gave the company an “overweight” rating in a research report on Tuesday, June 18th. Wolfe Research raised shares of Qiagen from a “peer perform” rating to an “outperform” rating and set a $50.00 price objective for the company in a report on Thursday, June 27th. Finally, Robert W. Baird lifted their price objective on shares of Qiagen from $49.00 to $52.00 and gave the company an “outperform” rating in a report on Friday, August 2nd. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, Qiagen has an average rating of “Moderate Buy” and an average target price of $50.25.

Qiagen Company Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.